Peptide Side Effects: The Complete Research Guide for Every Major Compound (2026)

Peptide Side Effects: The Research Perspective

The question of peptide side effects is one of the most important in research protocol design. Unlike pharmaceutical drugs, which often carry well-characterised adverse event profiles from large Phase 3 trials, many research peptides have side effect data primarily from preclinical animal studies and smaller human observational reports. This guide compiles what the research actually shows for each major compound.

The general principle across the peptide class is that side effects are typically mild, transient, and dose-dependent — a profile that reflects the fact that most research peptides mimic or modulate naturally occurring biological signals rather than introducing entirely foreign chemistry.

---

Collagen Peptide Side Effects

Collagen peptide side effects are among the most benign in the entire peptide category, consistent with collagen's status as a naturally occurring structural protein. Documented effects include:

• Digestive discomfort — mild bloating or heaviness, particularly at high doses (>20g/day); typically resolves with dose reduction
• Hypercalcaemia risk — rare; associated with collagen supplements derived from calcium-rich marine sources
• Allergic reactions — uncommon; most frequently reported in individuals with fish or shellfish allergies when using marine collagen

Collagen peptides have no documented serious adverse events in the published literature at standard research doses.

---

BPC-157 Peptide Side Effects

BPC 157 peptide side effects are remarkably mild given the compound's potency in preclinical models. Across hundreds of animal studies and growing human observational data, the documented effects are:

• Injection site reactions — mild redness or swelling at the subcutaneous injection site; transient
• Nausea — occasional with oral administration; rare with injectable
• Vivid dreams — anecdotally reported; mechanism unclear
• Temporary dizziness — rare; associated with rapid dose escalation

No serious adverse events have been reported in the BPC-157 preclinical literature. The compound has been studied at doses up to 100x the standard research dose in rodent models without toxicity signals.

---

GHK-Cu Peptide Side Effects

GHK-Cu peptide side effects and GHK peptide side effects are minimal, consistent with the compound's status as a naturally occurring copper-binding tripeptide found in human plasma. Research-documented effects include:

• Skin irritation — mild redness or tingling at topical application sites; typically resolves within hours
• Temporary copper taste — reported with high-dose injectable protocols
• Transient headache — rare; associated with injectable administration

GHK-Cu has an excellent safety profile in both topical and injectable research applications. It is one of the most studied cosmetic peptides with decades of safety data.

---

RETA Peptide Side Effects

Reta peptide side effects (Retatrutide) are consistent with the GLP-1 receptor agonist class:

• Nausea — most common during dose escalation; typically resolves within 2–4 weeks
• Vomiting — less frequent than nausea; managed by slowing escalation
• Diarrhoea — reported in ~20% of Phase 2 participants at higher doses
• Constipation — particularly at maintenance doses
• Injection site reactions — mild, transient

No serious cardiovascular safety signals were identified in Phase 2 trials. See the full Retatrutide research guide for complete clinical trial data.

---

Sermorelin Peptide Side Effects

Sermorelin peptide side effects are well-characterised from clinical use as a growth hormone deficiency diagnostic and therapeutic agent:

• Injection site reactions — the most common effect; mild redness, pain, or swelling
• Flushing — transient facial warmth, particularly with higher doses
• Headache — reported in approximately 5–10% of subjects in clinical studies
• Nausea — mild and infrequent
• Dizziness — rare
• Water retention — mild, associated with GH-mediated sodium retention

Sermorelin does not suppress endogenous growth hormone production — it stimulates the pituitary to produce GH naturally, which is a key safety advantage over exogenous GH administration.

---

Glow Peptide Side Effects

Glow peptide side effects (GHK-Cu-based blend formulations marketed under the Glow name) mirror the GHK-Cu profile described above, with the addition of any co-formulated compounds. The most commonly reported effects are:

• Injection site reactions — mild redness or bruising at the subcutaneous injection site
• Temporary skin flushing — particularly with higher doses
• Mild headache — transient, typically resolving within a few hours

Glow peptide formulations are generally very well tolerated. See the dedicated Glow Peptide research guide for full protocol and dosing information.

---

KPV Peptide Side Effects

KPV peptide side effects are minimal. KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-MSH with potent anti-inflammatory properties. Documented effects:

• Injection site reactions — mild, transient
• Temporary fatigue — rare; reported with higher doses

KPV has a strong safety profile in preclinical inflammatory bowel disease models, where it has been studied extensively without toxicity signals.

---

MOTS-C Peptide Side Effects

MOTS-C peptide side effects are not well-characterised due to the compound's relatively recent discovery (2015). Available preclinical data suggests:

• Injection site reactions — standard subcutaneous injection effects
• Transient fatigue — reported in some rodent models at high doses

No serious adverse events have been reported in the MOTS-C preclinical literature. Human data is limited to small observational studies.

---

Tesamorelin Peptide Side Effects

Tesamorelin peptide side effects are well-characterised from its FDA-approved use (Egrifta) for HIV-associated lipodystrophy:

• Injection site reactions — the most common effect; reported in up to 25% of patients in clinical trials
• Fluid retention / oedema — GH-mediated; typically mild
• Arthralgia — joint pain, particularly in the hands and wrists
• Carpal tunnel syndrome — associated with GH-mediated fluid retention; reversible on discontinuation
• Hyperglycaemia — mild elevations in fasting glucose; monitor in subjects with pre-existing glucose dysregulation
• Nausea — infrequent

Tesamorelin has the most extensive human safety database of any GHRH analogue, providing a useful reference for related compounds.

---

HGH Peptide Side Effects

HGH peptide side effects (growth hormone secretagogues including CJC-1295, Ipamorelin, and GHRP-2) are generally mild compared to exogenous HGH:

• Injection site reactions — standard
• Water retention — mild, GH-mediated
• Increased appetite — particularly with ghrelin-mimetic compounds (GHRP-2, GHRP-6)
• Tingling or numbness — hands and feet; associated with GH-mediated fluid shifts
• Transient cortisol and prolactin elevation — with GHRP-2 and GHRP-6; less pronounced with Ipamorelin

Ipamorelin is specifically noted for its selectivity — it stimulates GH release without the cortisol and prolactin elevations seen with other GHRPs, making it the preferred secretagogue in most research protocols.

---

AOD-9604 Peptide Side Effects

AOD 9604 peptide side effects are minimal. AOD-9604 is a fragment of the HGH molecule (amino acids 176–191) that retains fat-metabolising activity without the growth-promoting effects of full HGH:

• Injection site reactions — mild, transient
• Headache — rare
• Nausea — infrequent

AOD-9604 completed Phase 3 clinical trials for obesity and received GRAS (Generally Recognised As Safe) status from the FDA — one of the strongest safety designations available for a research compound.

---

PT-141 Peptide Side Effects

PT 141 peptide side effects (Bremelanotide) are well-characterised from its FDA approval (Vyleesi) for hypoactive sexual desire disorder in premenopausal women:

• Nausea — the most common effect; reported in ~40% of subjects in clinical trials; typically resolves within 2 hours
• Flushing — facial warmth and redness; transient
• Headache — reported in approximately 11% of subjects
• Injection site bruising — common with subcutaneous administration
• Transient blood pressure elevation — typically 2–4 mmHg systolic; resolves within 12 hours
• Hyperpigmentation — with repeated use; focal darkening of the face, gums, or breasts

---

CJC Peptide Side Effects

CJC peptide side effects (CJC-1295, with or without DAC) are consistent with the GHRH analogue class:

• Injection site reactions — mild redness or swelling
• Flushing — transient facial warmth
• Water retention — mild, GH-mediated
• Headache — infrequent
• Tingling — hands and feet; associated with GH-mediated fluid shifts

CJC-1295 with DAC (Drug Affinity Complex) has a longer half life (~8 days) than CJC-1295 without DAC (~30 minutes), which affects the duration of any side effects experienced.

---

DSIP Peptide Side Effects

DSIP peptide side effects (Delta Sleep-Inducing Peptide) are minimal in the available literature:

• Drowsiness — consistent with the compound's primary mechanism; typically the intended effect in sleep research protocols
• Headache — rare
• Injection site reactions — standard

DSIP has a very short half life (~30 minutes) and does not accumulate with repeated dosing, which limits the potential for side effect accumulation.

---

NAD Peptide Side Effects

NAD peptide side effects (NAD+ precursors and related compounds) are well-characterised from extensive human use:

• Flushing — the most common effect with IV NAD+ administration; described as a warm, uncomfortable sensation
• Nausea — common with rapid IV infusion; managed by slowing the infusion rate
• Headache — reported during and after IV administration
• Fatigue — paradoxical tiredness reported by some subjects during the first 1–2 days
• Injection site reactions — with subcutaneous administration

Oral NAD+ precursors (NMN, NR) have a more benign side effect profile, with mild GI effects being the most common complaint.

---

SLU-PP-332 Peptide Side Effects

SLU PP 332 peptide side effects are not yet well-characterised, as the compound is in early preclinical development. Available rodent data suggests:

• Cardiovascular effects — SLU-PP-332 activates ERR nuclear receptors involved in cardiac metabolism; cardiovascular monitoring is recommended in research protocols
• Metabolic effects — significant changes in glucose and lipid metabolism are expected given the compound's mechanism

Researchers should treat SLU-PP-332 as an early-stage compound with limited safety data and design protocols accordingly.

---

Copper Peptide Side Effects

Copper peptide side effects (including GHK-Cu and related copper-binding peptides) are generally mild:

• Skin irritation — redness or tingling at topical application sites
• Temporary discolouration — slight greenish tint to skin at high-concentration topical application sites; resolves with washing
• Copper taste — with injectable protocols at higher doses

Copper peptides have an extensive safety record in cosmetic dermatology, where they have been used for decades in topical formulations.

---

General Principles: Minimising Peptide Side Effects

Across all research peptides, the following principles consistently reduce side effect incidence:

1. Start low, titrate slowly — begin at the lower end of the research dose range and increase gradually
2. Use verified, HPLC-tested compounds — impurities in low-quality peptides are a major source of unexpected side effects
3. Correct reconstitution — use bacteriostatic water and store reconstituted peptides at 4°C
4. Rotate injection sites — prevents local tissue reactions from accumulating at a single site
5. Document observations — systematic recording of effects enables pattern recognition and protocol adjustment

---

Research Compliance Notice: All compounds supplied by Pure Peptides are for laboratory and preclinical research use only. They are not intended for human therapeutic use. Researchers are responsible for compliance with all applicable institutional, national, and international regulations.

---

All compounds are sold for laboratory research use only. Researchers are responsible for compliance with all applicable institutional and regulatory guidelines.